Literature DB >> 19582848

High molecular weight blood group A trisaccharide-polyacrylamide glycoconjugates as synthetic blood group A antigens for anti-A antibody removal devices.

Azadeh Alikhani1, Elena Y Korchagina, Alexander A Chinarev, Nicolai V Bovin, William J Federspiel.   

Abstract

Specific immunoadsorption of blood group antibodies by synthetic antigens immobilized on support matrices in the peri-transplantation period provides a promising solution to hyperacute rejection risk following ABO-incompatible transplantation. In this study, we investigated binding interactions between anti-A antibodies and synthetic blood group A trisaccharide conjugated with polyacrylamide of different molecular weights (30 and 1000 kDa). The glycopolymers were equipped with biotin tags and deposited on streptavidin-coated sensor chips. The affinity and kinetics of anti-A antibodies binding to glycoconjugates were studied using surface plasmon resonance (SPR). The high molecular weight conjugate (Atri-PAA(1000)-biotin) enhanced antibody binding capacity by two to three fold compared with the low molecular weight conjugate (Atri-PAA(30)-biotin), whereas varying the carbohydrate content in Atri-PAA(1000)-biotin (20 mol % or 50 mol %) did not affect antibody binding capacity of the glycoconjugate. The obtained results suggest that immunoadsorption devices, especially hollow fiber-based antibody filters which are limited in available surface area for antigen immobilization, may greatly benefit from the new synthetic high molecular weight polyacrylamide glycoconjugates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19582848      PMCID: PMC5944835          DOI: 10.1002/jbm.b.31466

Source DB:  PubMed          Journal:  J Biomed Mater Res B Appl Biomater        ISSN: 1552-4973            Impact factor:   3.368


  42 in total

1.  The ABO blood group system: historical background.

Authors:  W M Watkins
Journal:  Transfus Med       Date:  2001-08       Impact factor: 2.019

2.  An analysis of transport resistances in the operation of BIAcore; implications for kinetic studies of biospecific interactions.

Authors:  M L Yarmush; D B Patankar; D M Yarmush
Journal:  Mol Immunol       Date:  1996-10       Impact factor: 4.407

3.  Experiences with known ABO-mismatched renal transplants.

Authors:  A D Bannett; R F McAlack; R Raja; A Baquero; M Morris
Journal:  Transplant Proc       Date:  1987-12       Impact factor: 1.066

4.  Direct and competitive kinetic analysis of the interaction between human IgG1 and a one domain analogue of protein A.

Authors:  R Karlsson; L Jendeberg; B Nilsson; J Nilsson; P A Nygren
Journal:  J Immunol Methods       Date:  1995-06-14       Impact factor: 2.303

5.  Engraftment and transfusion requirements after allogeneic marrow transplantation for patients with acute non-lymphocytic leukemia in first complete remission.

Authors:  W Bensinger; F B Petersen; M Banaji; C D Buckner; R Clift; S J Slichter; R Storb; E D Thomas
Journal:  Bone Marrow Transplant       Date:  1989-07       Impact factor: 5.483

6.  High molecular weight neoglycoconjugates for solid phase assays.

Authors:  Nadezhda V Shilova; Oxana E Galanina; Tatyana V Pochechueva; Alexander A Chinarev; Vasily A Kadykov; Alexander B Tuzikov; Nicolai V Bovin
Journal:  Glycoconj J       Date:  2005-02       Impact factor: 2.916

7.  Specific removal of anti-A and anti-B antibodies by using modified dialysis filters.

Authors:  M S Hout; K E LeJeune; T M Schaack; D K Bristow; W J Federspiel
Journal:  ASAIO J       Date:  2000 Nov-Dec       Impact factor: 2.872

8.  In vitro assessment of a new ABO immunosorbent with synthetic carbohydrates attached to sepharose.

Authors:  Lennart Rydberg; Anders Bengtsson; Ola Samuelsson; Kurt Nilsson; Michael E Breimer
Journal:  Transpl Int       Date:  2004-11-17       Impact factor: 3.782

9.  Monoclonal anti-A antibody removal by synthetic A antigen immobilized on specific antibody filters.

Authors:  Shalini Gautam; Elena Y Korchagina; Nicolai V Bovin; William J Federspiel
Journal:  Biotechnol Bioeng       Date:  2008-03-01       Impact factor: 4.530

10.  Specificity of monoclonal antibodies against ABH and related structures tested by ELISA with synthetic glycoconjugates.

Authors:  R Rieben; E Y Korchagina; N V Bovin; M R Daha
Journal:  Transfus Clin Biol       Date:  1997       Impact factor: 1.406

View more
  2 in total

Review 1.  40 years of glyco-polyacrylamide in glycobiology.

Authors:  Alexander Tuzikov; Alexander Chinarev; Nadezhda Shilova; Elena Gordeeva; Oxana Galanina; Tatyana Ovchinnikova; Marcel Schaefer; Nicolai Bovin
Journal:  Glycoconj J       Date:  2021-01-14       Impact factor: 2.916

Review 2.  On the dark side of therapies with immunoglobulin concentrates: the adverse events.

Authors:  Peter J Späth; Guido Granata; Fabiola La Marra; Taco W Kuijpers; Isabella Quinti
Journal:  Front Immunol       Date:  2015-02-05       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.